Clinical trials in children with attention-deficit hyperactivity disorder (ADHD) show variability in behavioral responses to the selective norepinephrine reuptake inhibitor atomoxetine. The objective of this study was to determine whether transcranial magnetic stimulation-evoked short interval cortical inhibition might be a biomarker predicting, or correlating with, clinical atomoxetine response. At baseline and after 4 weeks of atomoxetine treatment in 7-to 12-year-old children with ADHD, transcranial magnetic stimulation short interval cortical inhibition was measured, blinded to clinical improvement. Primary analysis was by multivariate analysis of covariance. Baseline short interval cortical inhibition did not predict clinical responses. However, paradoxically, after 4 weeks of atomoxetine, mean short interval cortical inhibition was reduced 31.9% in responders and increased 6.1% in nonresponders (analysis of covariance t 41 ¼ 2.88; P ¼ .0063). Percentage reductions in short interval cortical inhibition correlated with reductions in the ADHD Rating Scale (r ¼ 0.50; P ¼ .0005). In children ages 7 to 12 years with ADHD treated with atomoxetine, improvements in clinical symptoms are correlated with reductions in motor cortex short interval cortical inhibition.
Attention-deficit hyperactivity disorder (ADHD), a highly prevalent neurobehavioral disorder, 1 is diagnosed empirically, based on major domains of impairment in attention, impulse control, and physical hyperactivity. Underlying neurophysiological mechanisms have been inferred primarily from correlative studies and may involve a variety of perturbations in the functional connectivity of neural networks contributing to cognition, motor control, and behavior. 2 Current ADHD pharmacotherapy emphasizes modulation of catecholamines with stimulant and nonstimulant medications, prescribed through a trial and error process with no quantitative, biologically based guidance. Atomoxetine is a selective norepinephrine reuptake inhibitor approved by the United States Food and Drug Administration (FDA) for the treatment of ADHD 3 that typically takes 4 weeks or more to achieve a clinical reduction in ADHD symptoms. Although a large fraction of children may respond reasonably well to either stimulants or atomoxetine, some children respond better to one and others do not respond to either. 4 This suggests 2 (or more) distinct underlying physiological characteristics predisposing children to respond preferentially to atomoxetine. 5 The objective of this study was to determine whether mechanisms linked to atomoxetine response may be easily and inexpensively identified in motor cortex using transcranial magnetic stimulation.
Transcranial magnetic stimulation has been used to evaluate motor cortex physiological biomarkers of both the diagnosis of ADHD and treatment-induced changes in ADHD. [6] [7] [8] [9] [10] Rationales for this approach include commonly observed impairments in fine motor control in ADHD 11 and neuroimaging findings in the frontal cortex and motor control systems. 12 Transcranial magnetic stimulation pulses noninvasively activate populations of neurons of the underlying cerebral cortex, producing local evoked potentials. Stimulating over hand motor cortex produces motor evoked potentials, easily measurable by surface electromyogram (EMG) in hand muscles, with amplitudes that reflect the local balance of inhibition and excitation. Paired-pulse transcranial magnetic stimulation protocols are widely used to activate excitatory or inhibitory neuronal populations in order to evaluate disorders involving synaptic transmission as well as to understand and quantify pharmacological effects. 13, 14 Paired subthreshold (conditioning)/suprathreshold (test) transcranial magnetic stimulation pulses delivered at an interstimulus interval of 3 ms activate the g-aminobutyric acid type A (GABA A )-mediated cortical inhibitory interneurons. This phenomenon is used to measure short interval cortical inhibition. 15 Short interval cortical inhibition appears to be altered in a number of neurological and psychiatric conditions. Previous studies have found significantly diminished short interval cortical inhibition in the dominant motor cortex of children 6, 10, 16 and adults 17, 18 with ADHD. Further, greater reductions in short interval cortical inhibition are found in children with more severe ADHD, particularly hyperactivity symptoms. 10, 19, 20 As would be expected, several studies have found that a single dose of the stimulant methylphenidate increases (''normalizes'') short interval cortical inhibition. 6, 8, 16 In a small prior study, the authors found that atomoxetine treatment in ADHD might paradoxically exert the opposite effect and reduce short interval cortical inhibition. 21 The aim of the current study was to determine in a larger study of children with ADHD whether changes induced by transcranial magnetic stimulation short interval cortical inhibition, assessed blinded to clinical improvement, would be a biomarker of atomoxetine response. Further, if atomoxetine reduces short interval cortical inhibition, opposing previously published studies showing that stimulants increase short interval cortical inhibition, the results of the present study would provide a foundation for future investigations to determine whether transcranial magnetic stimulation short interval cortical inhibition might differentiate distinct mechanisms of ADHD treatment responses or distinguish treatment-responsive ADHD subgroups.
Methods and Materials Subjects
Children with ADHD aged 7 to 12 years were recruited through clinic referrals and from community advertisement. Typically, subjects and their guardians either were seeking their first medication treatment for ADHD or were specifically seeking atomoxetine. Participants previously treated with stimulants were eligible, but subjects adequately maintained on any effective ADHD medication regimen were excluded.
The rationale for recruitment was to study a clinically relevant, generalizable population of children who would present to a clinician seeking ADHD treatment with atomoxetine. Eligibility requirements included a diagnosis of either combined or inattentive type ADHD as determined by a structured interview with the Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime Version. 22 Children with both predominantly inattentive and combined type ADHD were allowed in order to increase generalizability, with the plan to statistically evaluate subtypes and symptom severity subscores. Severity of ADHD symptom burden was confirmed by an ADHD Rating Scale score of at least 1.5 standard deviations higher than age/gender means by ADHD subtype. Further confirmation of symptom spectrum was obtained through Swanson, Nolan, and Pelham (SNAP)-IV-Parent 23 ratings. Clinical ratings of anxiety symptoms were assessed with the Pediatric Anxiety Rating Scale. 24 Cognitive ability was screened using the Wechsler Abbreviated Scales of Intelligence. 25 Children with estimated full-scale IQ of lower than 75 were excluded. Comorbidity was allowed, but ADHD must have been the primary diagnosis and focus of treatment. Study participants underwent comprehensive health history, review of systems, physical examination, laboratory measures including complete blood count, basic chemistries with liver panel, thyroid function test, urinalysis, pregnancy test (if relevant), and electrocardiogram (ECG). Any child who had a medical condition requiring pharmacological treatment that would interact with atomoxetine or for which atomoxetine would be contraindicated was excluded.
Written informed consent to participate in the study was obtained from parents/guardians with assent obtained from child subjects. The study was conducted jointly in the department of psychiatry at the University of Cincinnati and the division of neurology at Cincinnati Children's Hospital Medical Center and was approved by the University of Cincinnati and Cincinnati Children's Hospital Medical Center institutional review boards.
Atomoxetine Treatment Protocol
Study duration was 6 weeks; the study involved 7 total visits, 1 per week, the first 2 of which were for baseline assessments collected while patients were off medication to determine consistency of ADHD scores. After completion of study baseline, participants presented to the Cincinnati Children's Hospital Medical Center transcranial magnetic stimulation laboratory for transcranial magnetic stimulation and stop signal reaction time studies. The transcranial magnetic stimulation team was blinded to ADHD severity scores. On the day after transcranial magnetic stimulation and stop signal reaction time studies, participants began daily treatment with openlabel administration of atomoxetine starting at 0.5 mg/kg. Participants returned to the outpatient psychiatry clinic weekly where the primary investigator (F.R.S.), blinded to transcranial magnetic stimulation results, evaluated participants for ADHD symptom severity (ADHD Rating Scale and Clinical Global Impression-Severity Scale), Clinical Global Impression of Improvement, vital signs, adverse events, and compliance (pill counts). Atomoxetine dosing was titrated weekly using available formulations (as recommended in the manufacturer's label), up to approximately 1.2 mg/kg/d or 60 mg daily, whichever was lower. The maximum dose was maintained for the final week. After 4 weeks of atomoxetine treatment, a final assessment of clinical response was made, and vital signs, adverse events, medication compliance, psychiatric symptoms, and final ADHD ratings were obtained. Participants then returned to the transcranial magnetic stimulation laboratory at Cincinnati Children's Hospital Medical Center for repeat transcranial magnetic stimulation studies and stop signal reaction time studies, blinded to clinical response status.
Categorical and Dimensional Assessment of Responder Status
The primary categorical outcome was the 4-week treatment responder status as rated by a trained child psychiatrist (F.R.S.), blinded to transcranial magnetic stimulation outcomes. Responses were stratified as a dichotomous variable (responder, nonresponder) based on two 7-point scales: Clinical Global Impression of Improvement and Clinical Global Impression-Severity Scale. 26 Responders at endpoint had to have both a Clinical Global Impression-Severity Scale of 1 (normal) or 2 (borderline ill) and a Clinical Global Impression of Improvement of 1 (very much improved) or 2 (much improved). All others were designated nonresponders. The secondary, dimensional outcome was the investigator-administered and scored DuPaul ADHD Rating Scale-IV. 27 This includes the Inattention and Hyperactivity/Impulsivity subscales, each consisting of 9 items scored 0 (never or rarely) to 3 (very often), with a maximum total score of 54. Dimensional clinical improvement was evaluated as a percentage change in the ADHD Rating Scale from baseline to 4 weeks.
Transcranial Magnetic Stimulation Studies
All transcranial magnetic stimulation studies were performed in the transcranial magnetic stimulation laboratory at Cincinnati Children's Hospital Medical Center using 2 Magstim 200 stimulators (www.mags tim.com) connected through a Bistim module to a double 70-mm figure-8 coil. The method has been previously published and described in detail. 10 In brief, motor-evoked potentials were measured at the first dorsal interosseous muscle of the dominant hand with Ag/Cl surface EMG electrodes, amplified, and filtered (100/1000 Hz) (Coulbourn Instruments, Allentown, Pennsylvania). Motor evoked potential amplitudes were recorded and stored using Signal software and a Micro1401 interface (Cambridge Electronic Design, Cambridge, United Kingdom). Resting motor threshold was the lowest intensity that would produce motor evoked potential amplitudes of at least 50 mV on 3 out of 6 consecutive stimulation trials. Active motor threshold was the lowest intensity reached that produced motor evoked potentials larger than background in 3 out of 6 trials while the subject was abducting the first finger against a ball. The cortical silent period was evaluated with 5 pulses administered at 1.5 times the active motor threshold during first dorsal interosseous activation.
Paired-pulse transcranial magnetic stimulation was used to evaluate short interval cortical inhibition and intracortical facilitation at rest. Each paired-pulse trial consisted of a subthreshold conditioning stimulus (at 60% of resting motor threshold) followed by a suprathreshold test pulse (at 110%-130% resting motor threshold) at an interstimulus interval of either 3 ms (short interval cortical inhibition) or 10 ms (intracortical facilitation). Thirty total trials consisting of ten single-pulse transcranial magnetic stimulations, ten 3-ms paired-pulse transcranial magnetic stimulations, and ten 10-ms paired-pulse transcranial magnetic stimulations were delivered in a random order, separated by 6% + 10% seconds. For paired-pulse transcranial magnetic stimulation, a ratio less than 1 indicates inhibition and greater than 1 indicates facilitation. The conditioning pulse intensity and interstimulus intervals were chosen based on robust results in prior ADHD studies. 10, 28, 29 Tracings with any artifact 200 ms prior to and 20 ms after the transcranial magnetic stimulation pulse were removed. Methods for reducing unwanted movement and motion artifact have been described previously. 10 
Behavioral Inhibition: Stop Task Paradigm
The stop task paradigm, designed for use with Presentation software (www.neurobs.com), consisted of trials with either (1) the primary ''Go'' instruction only, a choice reaction time test in which participants are instructed to press either ''X'' or ''O'' buttons on a game controller as quickly as possible in response to visual cue; or (2) the secondary ''Stop'' task, a response inhibition test in which participants are instructed to withhold pressing a button when, following the ''X'' or ''O'' visual Go cue, they hear a Stop tone. 30 After 1 practice block, there were 4 blocks that consisted of 24 trials: 18 Go and 6 Stop. Each trial consisted of 500 ms of a fixation point, followed by a 1000-ms Go task (X or O, without or with a Stop tone), followed by a blank screen for 2000 ms. Auditory stop signal timing was delivered 50 ms later after a successful stop trial, making inhibition more difficult, and 50 ms earlier after failure, making inhibition easier. Thus, the stop signal latency automatically adjusted to result in a 50% success rate. This allowed for an estimated stop signal reaction time as the difference between the mean choice reaction time and the mean stop signal delay.
Statistical Analysis and Evaluation for Potential Confounders
Statistical analyses were performed with SAS version 9.3 (www.SAS. com). Primary analysis to determine whether mean motor cortex inhibition (short interval cortical inhibition) changes differed in atomoxetine responders versus nonresponders was performed with analysis of covariance. The primary dependent variable was 4-week short interval cortical inhibition. The primary predictor was atomoxetine response status. Baseline short interval cortical inhibition and age were planned covariates. Because ADHD subtype and ADHD Rating Scale scores differed in the response groups (see Results), these were evaluated as possible confounders. First, ADHD subtype and baseline ADHD Rating Scale were added to the model and tested as interaction terms with treatment response category. The interactions were not significant. Second, the ADHD subtype and ADHD Rating Scale were added individually to the primary analysis of covariance to test for significance and were found to be far from significant (ADHD Rating Scale P ¼ .78; ADHD subtype P ¼ .84). As there was no significant degree of interaction among the covariates, a main-effects model could be applied. Adjusted means and 95% confidence intervals were calculated. Intracortical facilitation and stop signal reaction time changes were similarly analyzed.
Secondary dimensional analysis of the relationship between ADHD and short interval cortical inhibition was performed calculating the Pearson correlation of the baseline to 4-week percentage changes in ADHD Rating Scale and in short interval cortical inhibition. Intracortical facilitation and stop signal reaction time correlations were similarly calculated.
Finally, exploratory analysis was performed to identify predictors of responder status. Simple t tests were performed to evaluate responder group differences in baseline and 4-week ADHD Rating Scale, stop signal reaction time, short interval cortical inhibition, intracortical facilitation, resting motor threshold, active motor threshold, and cortical silent period.
A higher number of children than expected had high baseline resting motor thresholds. As a result, no short interval cortical inhibition was obtainable in a large number of participants. To clarify generalizability of the results of the main analysis, demographic and clinical features were compared between children whose short interval cortical inhibition was obtainable versus those in whom it was not.
Results

Demographics
The study sample was comprised of 108 children, including 95 children analyzed who had clinical data at study onset and after 4 weeks of treatment. Thirteen children were enrolled and not included either because they dropped out prior to the firstdose visit (n ¼ 6) or because they failed to follow up and violated study protocols after the first dose (n ¼ 7). Demographics of the analyzed sample were as follows: sex, 63 males (66%), 32 females (34%); race, 63 Caucasian (66%), 26 African American (27%), 6 mixed (6%); ethnicity, 4 Hispanic (4%). Hand dominance was 79 right-handed (83%), 15 left-handed (16%), and 1 mixed dominance.
Adverse Events
There were no serious adverse events recorded due to either atomoxetine or participation in transcranial magnetic stimulation studies. Other adverse events were mild and consistent with those reported in clinical trials of atomoxetine. 3, 4 Clinical, Behavioral, and Physiological Assessments Demographics and ADHD scores at baseline are shown in Table 1 . Clinical responses were obtained in all 95 subjects at baseline and 4 weeks. Stop signal was attempted in all subjects, but in 11 subjects there was poor effort, the children did not understand the game, or the percentage of successful inhibition was below 35% so that the stop signal reaction time was considered invalid. Transcranial magnetic stimulation was attempted in all subjects. Active motor thresholds were attainable in 86 and resting motor thresholds in 78. In the remainder of cases there was no elicitable resting motor threshold at 100% of stimulator intensity. If the single-pulse transcranial magnetic stimulation amplitudes were not consistently greater than 300 mV, then short interval cortical inhibition and intracortical facilitation were not obtainable or not valid. Short interval cortical inhibition was obtained at both visits in 45 participants (47%).
Clinical Improvement
ADHD Rating Scale scores at baseline and after treatment are shown in Figure 1 . Fifty-two participants (54%) met criteria as responders and the remaining 43 (46%) as nonresponders. In the responder group, there was a mean 69% (25-point) reduction in ADHD Rating Scale. In the nonresponder group, there was a mean 24% (10-point) reduction in ADHD Rating Scale. Most had previously tried stimulants (58%). Comparison of demographic and clinical ratings and ADHD Rating Scale scores at baseline are found in Table 1 . Nonresponders were younger and had higher mean ADHD Rating Scale scores.
Motor Cortex Inhibition and Excitation Changes Stratified by Clinical Response to Atomoxetine
Mean (raw) short interval cortical inhibition at baseline and after treatment is shown in Figure 2 . After 4 weeks of treatment, atomoxetine responders had significantly less short interval cortical inhibition (higher ratios, approaching 1.0, indicate less inhibition). Estimated mean posttreatment short interval cortical inhibition in responders was 0.66 (standard error, 0.051), that is, 34% inhibition; in nonresponders, short interval cortical inhibition was 0.44 (standard error, 0.057), that is, 56% inhibition (analysis of covariance t 41 ¼ 2.88; P ¼ .0063). Intracortical facilitation at baseline and after treatment is shown in Figure 3 . After 4 weeks of treatment, atomoxetine responders had, at the trend level, higher intracortical facilitation. Estimated mean posttreatment intracortical facilitation in responders was 1.40 (standard error, 0.095) (40% facilitation); in nonresponders, intracortical facilitation was 1.13 (standard error, 0.11) (13% facilitation) (analysis of covariance t 41 ¼ 1.88; P ¼ .067).
Correlations Between Changes in ADHD Rating Scale and Short Interval Cortical Inhibition, Intracortical Facilitation, and Stop Signal Reaction Time
Consistent with the primary categorical analysis, decreases in short interval cortical inhibition correlated with decreases in ADHD Rating Scale total (r ¼ 0.50; P ¼ .0005), attention subscore (r ¼ 0.42; P ¼ .005), and hyperactivity/impulsivity subscore (r ¼ 0.44; P ¼ .003).
There was no significant correlation between change in stop signal reaction time or change in intracortical facilitation and change in ADHD Rating Scale.
Other Transcranial Magnetic Stimulation Measures
Baseline and posttreatment univariate treatment effects are shown in Table 2 . There were no significant differences in resting motor threshold, active motor threshold, or cortical silent period.
Response Inhibition
Baseline and posttreatment response inhibition findings are shown in Table 2 . Stop signal reaction time improved in both clinical responders and nonresponders.
Assessments of Children for Whom Short Interval Cortical Inhibition Was Not Obtainable
Children for whom short interval cortical inhibition was not obtainable were younger (mean 9.1 vs 10.4 years; P < .001) and had higher resting motor threshold (mean 82 vs 58; P < .001). However, the proportion of responders was not different (54% vs 55%), and baseline ADHD Rating Scale did not differ (mean 38.2 vs 37.4; P not significant).
Discussion
The primary finding of this study is that children with ADHD who respond clinically to atomoxetine have a decrease in transcranial magnetic stimulation-evoked short interval cortical inhibition. In contrast, after 4 weeks of atomoxetine treatment, short interval cortical inhibition did not change in nonresponders. The dimensional analysis supported this finding: After atomoxetine treatment, the percentage of reduction in parent-rated ADHD symptoms correlated with the percentage of reduction in short interval cortical inhibition.
The objective of this study was to identify a biomarker correlating with treatment response to atomoxetine. Short interval cortical inhibition was selected as a primary candidate based on case-control studies showing reduced short interval cortical inhibition in ADHD and correlations between less short interval cortical inhibition and greater ADHD symptom severity. 7, 10, 16, 20 Moreover, in prior studies, short interval cortical inhibition did appear to be sensitive to single doses of 
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Effects of single doses of medication on short interval cortical inhibition have varied. 31 Thus, more research was needed to clarify whether short interval cortical inhibition would be a consistent biomarker of treatment response in ADHD. The direction of short interval cortical inhibition change is paradoxical, in that the change correlating with clinical benefit is not in the direction of ''normality.'' Stimulant-evoked increases in short interval cortical inhibition have been found in prior single-dose studies and suggest that stimulants may normalize a deficiency in inhibition in some children with ADHD. 6 Although at this time the authors can only speculate on the underlying neurobiological explanation, there are few studies looking at more than single-dose responses. Moreover, our results are consistent with our prior, smaller study in children with Tourette syndrome and ADHD, where 1 month of atomoxetine treatment also reduced mean short interval cortical inhibition, correlating with ADHD improvement. 21 The consistent results of the present, larger study suggest that this seemingly paradoxical finding is a reproducible indicator of atomoxetine treatment response in ADHD.
The authors designed this study to optimize the measure of interest, short interval cortical inhibition, by selecting a conditioning pulse intensity to evoke moderate short interval cortical inhibition while being lower than is optimal for facilitation. Another possible explanation for the apparent reduction in short interval cortical inhibition would be an unexpected atomoxetine effect on short interval facilitation. Short interval facilitation is a paired-pulse phenomenon elicitable at intervals that overlap with those of short interval cortical inhibition, 32, 33 and thus it may contaminate short interval cortical inhibition assessment. However, there are several reasons for interpreting this possibility cautiously. First, the optimal short interval cortical inhibition and short interval facilitation pulse intensities are quite different. For short interval facilitation the first pulse is suprathreshold, whereas for short interval cortical inhibition it is subthreshold. At the pulse intensities in the current experiment, short interval cortical inhibition effects should be much more robust than short interval facilitation ones, and therefore it seems unlikely that this excitation would dominate inhibition. 29 Second, as recently shown, dopamine deficiency in Parkinson disease is linked to increased short interval facilitation, and dopamine replacement in Parkinson disease reduces short interval facilitation. 34 So to the extent to which levodopa, stimulants, and atomoxetine may all increase dopamine levels in cerebral cortex, 35, 36 it is not readily apparent why atomoxetine would increase short interval facilitation in ADHD. Future studies evaluating both short interval cortical inhibition and short interval facilitation, similar to those recently done in Parkinson disease, may be helpful.
Significant potential limitations to this study include the open-label design, the subjective nature of the parent rating scales of ADHD, and the fairly short, 4-week treatment period. In powering the study, the authors anticipated an approximate response rate at 4 weeks of 50%, which turned out to be fairly accurate. This 50:50 ratio would make it more difficult to have across-the-board positive expectancy about physiological changes. Moreover, transcranial magnetic stimulation generates objective, quantitative measures, and all experiments and analyses were performed blinded to treatment results. Thus, while lack of blinding may have influenced parental perceptions, this would not have introduced much bias into the transcranial magnetic stimulation findings. It would be surprising, for example, if the degree of ''placebo response'' to atomoxetine correlated with degree of change in short interval cortical inhibition, although this possibility cannot be excluded in the absence of a true placebo. The stop signal reaction time was used to evaluate response inhibition at baseline and after treatment. The pretreatment findings were broadly consistent with those in other studies. The authors were surprised that there appeared to be a substantial improvement in stop signal reaction time in both clinical responders and nonresponders. It is possible that atomoxetine fairly consistently improved the capacity to inhibit in the laboratory but that this did not generalize to improved behavior in the home or classroom. A practice effect may also have occurred. The physiological process underlying these changes in stop signal reaction time appears to be distinct also from short interval cortical inhibition and intracortical facilitation, as these did not correlate with one another (not shown).
A significant limitation of this technique in the current population was higher than expected resting depolarization thresholds. This appears to be primarily due to the inclusion of younger children in this cohort. 10 This meant that a much smaller fraction of children than expected had short interval cortical inhibition measured. Comparison of those in whom short interval cortical inhibition was and was not measurable suggests that the main difference was younger age and therefore higher motor thresholds. 37 With regard to implications for ADHD generalizability, the study did not reveal evidence of a difference in ADHD symptoms in children with higher thresholds, in whom short interval cortical inhibition was not measurable.
In summary, paradoxical changes in motor cortex inhibitory physiology appear to reflect behavioral improvements following use of atomoxetine in children with ADHD. The authors did not find evidence that baseline short interval cortical inhibition, in isolation, predicts treatment responses. More research is needed to clarify both excitatory and inhibitory components to these responses, to explain clinical heterogeneity, and to predict atomoxetine treatment responses in advance.
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